H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
Wainwright reaffirmed a Buy rating and lifted its price target for Cogent Biosciences, Inc. (NASDAQ:COGT) from $50 to $52. The firm stated that it anticipated an uneventful FDA review procedure for bezuclastinib in cases of non-advanced systemic mastocytosis. Cogent Biosciences, Inc. (NASDAQ:COGT) filed a New Drug Application for bezuclastinib in NonAdvanced Systemic Mastocytosis with the US Food and Drug Administration on December 30, 2025. This submission comes after the Breakthrough Therapy Designation for bezuclastinib in patients with smoldering systemic mastocytosis and NonAdvSM patients who were previously treated with avapritinib. It is based on favorable clinical data from the SUMMIT pivotal trial. All of the major and important secondary outcomes of the SUMMIT study were statistically significant. Bezuclastinib exhibited a therapeutic effect in every symptom domain, including improvements in the most severe baseline symptom as well as 11 patient-specific symptoms. Improvem
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies PortfolioGlobeNewswire
- Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences (NASDAQ:COGT) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
COGT
Sec Filings
- 1/5/26 - Form 4
- 12/30/25 - Form 4
- 12/30/25 - Form 4
- COGT's page on the SEC website